Aardvark Therapeutics (AARD) – Investment Analysts’ Recent Ratings Updates

Aardvark Therapeutics (NASDAQ: AARD) has recently received a number of price target changes and ratings updates:

• 12/23/2025 – Aardvark Therapeutics is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $35.00 price target on the stock.
• 12/22/2025 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/12/2025 – Aardvark Therapeutics is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
• 12/8/2025 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/2/2025 – Aardvark Therapeutics is now covered by analysts at Raymond James Financial, Inc.. They set a “strong-buy” rating and a $47.00 price target on the stock.
• 12/2/2025 – Aardvark Therapeutics is now covered by analysts at Raymond James Financial, Inc.. They set a “strong-buy” rating and a $47.00 price target on the stock.
• 12/1/2025 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/14/2025 – Aardvark Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 11/14/2025 – Aardvark Therapeutics had its price target lowered by analysts at Royal Bank Of Canada from $19.00 to $18.00. They now have an “outperform” rating on the stock.
• 11/13/2025 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/7/2025 – Aardvark Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $26.00 price target on the stock.

Insider Buying and Selling at Aardvark Therapeutics

In other news, CEO Tien-Li Lee purchased 7,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average cost of $14.48 per share, with a total value of $101,360.00. Following the completion of the purchase, the chief executive officer owned 1,551,613 shares in the company, valued at approximately $22,467,356.24. This represents a 0.45% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Nelson Sun acquired 3,000 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $14.40 per share, for a total transaction of $43,200.00. Following the completion of the acquisition, the chief financial officer directly owned 108,484 shares in the company, valued at approximately $1,562,169.60. This represents a 2.84% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.